I wrote a piece for University of Queensland’s celebration of International Women’s Day.
This is me getting my last Zometa infusion to help my bones remain strong. A common side effect of Arimidex (aromatase inhibitor) is (a tendency toward early onset) osteoporosis.
The kicker with Zometa is that if you take it for too long it increases your chances of bone fractures at the joint – as opposed to keeping your bones healthier. Side effects oh side effects.
My oncologist checked my bone density and as I was just within normal limits, I’ve gone off it. You can also take Prolia which you can inject (or get injected) into subcutaneous fat.
October 24, 2017
New research which has dramatically expanded the number of known risk factors for breast cancer is set to pave the way for earlier screening and better drugs for those in the disease’s firing line.
The world’s biggest genetic study of the illness has uncovered 72 new variants that put women at higher danger and could allow screening for women with family histories of breast cancer in their 20s or 30s. Revealed this morning in two Nature journals, the study casts new light on family risk factors for breast cancer and provides insight into how genetic variations, which pose little danger on their own, can combine to increase the risk of contracting breast cancer.
The international effort involved 550 researchers from about 300 institutions including six universities, five hospitals, a charity and two medical research institutes in Australia. Collectively they analysed data from 275,000 women, more than half of whom were diagnosed with breast cancer.
While mutations in well-studied genes like BRCA1 and BRCA2 boost the probability of contracting the disease, more than 100 less consequential variants — which pose little danger individually, but considerable risk collectively — had already been implicated. The new study raises that number to about 180, explaining a further 18 per cent of the “familial relative risk” for breast cancer.
Co-lead author Georgia Chenevix-Trench, of the QIMR Berghofer Medical Research Institute in Brisbane, said tests for the markers could highlight women who warranted early mammograms or MRIs. The insights could be particularly helpful in determining whether and when women at high risk, because of BRCA mutations, should have preventive surgery. The “genotyping” tests would measure several hundred variants, as opposed to full genome sequencing which is far more expensive. Professor Chenevix-Trench said such tests were already being used in research, and could be clinically available in a few years.
Brisbane author Josie Dietrich said such tests “would have saved me a great deal of suffering. I would have had a chance of having a second child.” Diagnosed with a “very aggressive” cancer at 35, she had a double mastectomy, a full hysterectomy and chemotherapy. Eight years later she still takes drugs that could cause osteoporosis, necessitating infusions twice a year to keep her bones strong.
The treatment and its effects are like a “chronic disease”, even though she is now clear of cancer. “I’ve gone through the menopause from hell, and I’m only 43. A geneticist said I had what’s called an unspecified inherited cluster, which means there are all these reasons I got cancer — but no one really knows why.”
Professor Chenevix-Trench said the findings could guide development of new drugs. While most of the suspect variants were found in “non-coding” parts of the genome — stretches of genetic material that do not generate proteins, long dismissed as “junk DNA” — they could help pinpoint proteins to be targeted.
QIMR Professor Georgia Chenevix-Trench et al. discovered ground breaking results on identifying 65 new breast cancer risk loci. doi:10.1038/nature24284
I got the results of my bone scan – all within normal limits. Relief.
The clinical nurse at the cancer care services I attend every 6 months has bumped another women’s appointment to squeeze me into seeing my oncologist next Monday (son in-tow). This is, allegedly, due to not being able to give my bone scan (CT) results over the phone.
You see …
I’m scared. I’m scared that my cancer’s return into places I can’t remove it.
It’s likely a very innocent, and decent, act by the cancer care services to move around appointments so that I can collect my son from school and still attend an appointment to hear from my oncologist whether I should continue prolio or zometa (to increase bone strength, and avoid or deter the onset of osteoporosis).
I’ll update next Monday on what the results are.